Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2019 Jan 30

PMID 30694319

Citations 218

Authors

Brian A Ference

John J P Kastelein

Kausik K Ray

Henry N Ginsberg

M John Chapman

Chris J Packard

Ulrich Laufs

Clare Oliver-Williams

Angela M Wood

Adam S Butterworth

Emanuele Di Angelantonio

John Danesh

Stephen J Nicholls

Deepak L Bhatt

Marc S Sabatine

Alberico L Catapano

Affiliations

Soon will be listed here.

Abstract

Importance: Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. It is unknown whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.

Objective: To compare the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) gene and LDL-C-lowering variants in the LDL receptor gene (LDLR) with the risk of cardiovascular disease per unit change in ApoB.

Design, Setting, And Participants: Mendelian randomization analyses evaluating the associations of genetic scores composed of triglyceride-lowering variants in the LPL gene and LDL-C-lowering variants in the LDLR gene, respectively, with the risk of cardiovascular events among participants enrolled in 63 cohort or case-control studies conducted in North America or Europe between 1948 and 2017.

Exposures: Differences in plasma triglyceride, LDL-C, and ApoB levels associated with the LPL and LDLR genetic scores.

Main Outcomes And Measures: Odds ratio (OR) for coronary heart disease (CHD)-defined as coronary death, myocardial infarction, or coronary revascularization-per 10-mg/dL lower concentration of ApoB-containing lipoproteins.

Results: A total of 654 783 participants, including 91 129 cases of CHD, were included (mean age, 62.7 years; 51.4% women). For each 10-mg/dL lower level of ApoB-containing lipoproteins, the LPL score was associated with 69.9-mg/dL (95% CI, 68.1-71.6; P = 7.1 × 10-1363) lower triglyceride levels and 0.7-mg/dL (95% CI, 0.03-1.4; P = .04) higher LDL-C levels; while the LDLR score was associated with 14.2-mg/dL (95% CI, 13.6-14.8; P = 1.4 × 10-465) lower LDL-C and 1.9-mg/dL (95% CI, 0.1-3.9; P = .04) lower triglyceride levels. Despite these differences in associated lipid levels, the LPL and LDLR scores were associated with similar lower risk of CHD per 10-mg/dL lower level of ApoB-containing lipoproteins (OR, 0.771 [95% CI, 0.741-0.802], P = 3.9 × 10-38 and OR, 0.773 [95% CI, 0.747-0.801], P = 1.1 × 10-46, respectively). In multivariable mendelian randomization analyses, the associations between triglyceride and LDL-C levels with the risk of CHD became null after adjusting for differences in ApoB (triglycerides: OR, 1.014 [95% CI, 0.965-1.065], P = .19; LDL-C: OR, 1.010 [95% CI, 0.967-1.055], P = .19; ApoB: OR, 0.761 [95% CI, 0.723-0.798], P = 7.51 × 10-20).

Conclusions And Relevance: Triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants were associated with similar lower risk of CHD per unit difference in ApoB. Therefore, the clinical benefit of lowering triglyceride and LDL-C levels may be proportional to the absolute change in ApoB.

Citing Articles

Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk.

Wang L, Jiang F, Sun J, Zhao J, He Y, Gill D Int J Epidemiol. 2025; 54(2).

PMID: 40064167 PMC: 11893152. DOI: 10.1093/ije/dyaf020.

A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular Disease.

Kalwick M, Roth M Nutrients. 2025; 17(4).

PMID: 40004987 PMC: 11858766. DOI: 10.3390/nu17040659.

Identification of tacrolimus-related genes in familial combined hyperlipidemia and development of a diagnostic model using bioinformatics analysis.

Xu Y, He H, Li H Heliyon. 2025; 11(3):e41705.

PMID: 39916852 PMC: 11800081. DOI: 10.1016/j.heliyon.2025.e41705.

Development and Validation of a Predictive Model Based on Serum Silent Information Regulator 6 Levels in Chinese Older Adult Patients: Cross-Sectional Descriptive Study.

You Y, Liang W, Zhao Y JMIR Aging. 2025; 8():e64374.

PMID: 39851250 PMC: 11758378. DOI: 10.2196/64374.

New Approaches to Lipoproteins for the Prevention of Cardiovascular Events.

Fujino M, Di Giovanni G, Nicholls S J Atheroscler Thromb. 2025; 32(3):265-280.

PMID: 39756980 PMC: 11883213. DOI: 10.5551/jat.RV22031.

References

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102(1):21-7. DOI: 10.1161/01.cir.102.1.21. View

Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500):1849-61. DOI: 10.1016/S0140-6736(05)67667-2. View

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y . Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567):1090-8. DOI: 10.1016/S0140-6736(07)60527-3. View

Mailman M, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R . The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007; 39(10):1181-6. PMC: 2031016. DOI: 10.1038/ng1007-1181. View

Ginsberg H, Elam M, Lovato L, Crouse 3rd J, Leiter L, Linz P . Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-74. PMC: 2879499. DOI: 10.1056/NEJMoa1001282. View

Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

Ference B, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A . Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25):2631-9. DOI: 10.1016/j.jacc.2012.09.017. View

10.

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen A, Frikke-Schmidt R, Nordestgaard B . Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2012; 61(4):427-436. DOI: 10.1016/j.jacc.2012.08.1026. View

11.

Willer C, Schmidt E, Sengupta S, Peloso G, Gustafsson S, Kanoni S . Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45(11):1274-1283. PMC: 3838666. DOI: 10.1038/ng.2797. View

12.

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002. View

13.

Jorgensen A, Frikke-Schmidt R, Nordestgaard B, Tybjaerg-Hansen A . Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371(1):32-41. DOI: 10.1056/NEJMoa1308027. View

14.

Nordestgaard B, Varbo A . Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943):626-635. DOI: 10.1016/S0140-6736(14)61177-6. View

15.

Ference B, Majeed F, Penumetcha R, Flack J, Brook R . Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015; 65(15):1552-61. PMC: 6101243. DOI: 10.1016/j.jacc.2015.02.020. View

16.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3):e1001779. PMC: 4380465. DOI: 10.1371/journal.pmed.1001779. View

17.

Gaudet D, Alexander V, Baker B, Brisson D, Tremblay K, Singleton W . Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015; 373(5):438-47. DOI: 10.1056/NEJMoa1400283. View

18.

Nikpay M, Goel A, Won H, Hall L, Willenborg C, Kanoni S . A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015; 47(10):1121-1130. PMC: 4589895. DOI: 10.1038/ng.3396. View

19.

Burgess S, Dudbridge F, Thompson S . Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2015; 35(11):1880-906. PMC: 4832315. DOI: 10.1002/sim.6835. View

20.

Dewey F, Gusarova V, ODushlaine C, Gottesman O, Trejos J, Hunt C . Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016; 374(12):1123-33. PMC: 4900689. DOI: 10.1056/NEJMoa1510926. View